5 Best Low Cost ETFs

3. iShares Core S&P 500 ETF (NYSE:IVV)

5-Year Share Price Performance as of April 15: 74.08%

The iShares Core S&P 500 ETF (NYSE:IVV) aims to replicate the performance of the S&P 500 Index. Launched on May 15, 2000, IVV is one of the best low cost ETFs. As of April 12, 2024, it holds a total of $440.07 billion in assets, with a portfolio consisting of 503 stocks. It features an expense ratio of 0.03%.

Eli Lilly and Company (NYSE:LLY) is one of the top holdings of the iShares Core S&P 500 ETF (NYSE:IVV). It is a global pharmaceutical company that focuses on discovering, developing, and marketing human pharmaceuticals. On March 15, Eli Lilly and Company (NYSE:LLY) made headlines as its weight loss drug Zepbound had outperformed Novo Nordisk A/S (NYSE:NVO)’s rival drug Wegovy in terms of new prescriptions in the US.

According to Insider Monkey’s fourth quarter database, 102 hedge funds were bullish on Eli Lilly and Company (NYSE:LLY), same as the last quarter. Ken Fisher’s Fisher Asset Management is the largest shareholder of the company, with 4.54 million shares worth $2.65 billion.

Aristotle Atlantic Core Equity Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2023 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S. from its top-selling drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment, Human pharmaceutical products.

Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology, immunology and central nervous system disorders. Currently, there are two phase three assets, Orforglipron, an oral GLP-1 and retatrutide, a triple incretin agonist, which have the potential to expand upon the potential success of Mounjaro. We believe that Mounjaro has the potential to commercialize beyond type 2 diabetes and obesity, potentially in the areas mentioned above of heart disease, sleep apnea, fatty liver disease and chronic kidney disease. We belief the premium valuation is supported by this outsized growth profile.”